CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review.

ABSTRACT: The cyclin D-CDK4/6 complexes play a pivotal role in controlling the cell cycle. Deregulation in cyclin D-CDK4/6 pathway has been described in many types of cancer and it invariably leads to uncontrolled cell proliferation. Many efforts have been made to develop a target therapy able to inhibit CDK4/6 activity. To date, three selective CDK4/6 small inhibitors have been introduced in the clinic for the treatment of hormone positive advanced breast cancer patients, following the impressive results obtained in phase III clinical trials. However, since their approval, clinical evidences have demonstrated that about 30% of breast cancer is intrinsically resistant to CDK4/6 inhibitors and that prolonged treatment eventually leads to acquired resistance in many patients. So, on one hand, clinical

SUBMITTER: Rampioni Vinciguerra GL 

PROVIDER: S-EPMC9197541 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature